The S&P 500 Index ($SPX ) (SPY ) today is up +1.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.55%, and the ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Days after the Supreme Court appeared skeptical of the legal backing for many of his tariffs, the president on social media Sunday lauded the revenue they have brought in and said the government would ...

Just as U.S. households were fretting about the effect on travel and the wider economy of the longest-ever government shutdown, the U.S. Senate on Sunday finally began the process of re-opening ...

Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and ...

Real-time index price for TSX Composite ESG Index (TXSG), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The ‘Big Short’ investor Michael Burry disclosed a new regulatory 13F filing on November 3, revealing several portfolio ...

Subscribe to the Stock Movers Podcast on Apple ... optimists growing concerned that all the good vibes are waving a contrarian red flag. Bulls have history on their side, as November is historically ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $26.5 for Pfizer over the last 3 months.

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.